Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xii 7. Preface - p. xiii 8. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis - p. 1 9. The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View - p. 11 10. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis - p. 23 11. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics - p. 39 12. The Genetics of Pediatric Nonalcoholic Fatty Liver Disease - p. 59 13. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography - p. 73 14. Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis - p. 93 15. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom - p. 109 16. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease - p. 121 17. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome - p. 133 18. The Role of Nonalcoholic Fatty Liver Disease on Cardiovascular Manifestations and Outcomes - p. 141 19. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis - p. 175 20. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis - p. 189 21. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma - p. 201 22. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation - p. 213
No hay muestra disponible
No hay ficha técnica disponible
Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xii 7. Preface - p. xiii 8. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis - p. 1 9. The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View - p. 11 10. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis - p. 23 11. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics - p. 39 12. The Genetics of Pediatric Nonalcoholic Fatty Liver Disease - p. 59 13. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography - p. 73 14. Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis - p. 93 15. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom - p. 109 16. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease - p. 121 17. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome - p. 133 18. The Role of Nonalcoholic Fatty Liver Disease on Cardiovascular Manifestations and Outcomes - p. 141 19. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis - p. 175 20. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis - p. 189 21. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma - p. 201 22. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation - p. 213
No hay muestra disponible
No hay ficha técnica disponible
